BR112021016673A2 - Receptores de antígeno chiméricos anticlaudina 18.2 humanizados e seus usos - Google Patents

Receptores de antígeno chiméricos anticlaudina 18.2 humanizados e seus usos Download PDF

Info

Publication number
BR112021016673A2
BR112021016673A2 BR112021016673-4A BR112021016673A BR112021016673A2 BR 112021016673 A2 BR112021016673 A2 BR 112021016673A2 BR 112021016673 A BR112021016673 A BR 112021016673A BR 112021016673 A2 BR112021016673 A2 BR 112021016673A2
Authority
BR
Brazil
Prior art keywords
seq
chain variable
variable region
polypeptide sequence
light chain
Prior art date
Application number
BR112021016673-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Minghan Wang
Hui Zou
Haiqun Jia
Original Assignee
Phanes Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phanes Therapeutics, Inc. filed Critical Phanes Therapeutics, Inc.
Publication of BR112021016673A2 publication Critical patent/BR112021016673A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021016673-4A 2019-03-29 2020-03-24 Receptores de antígeno chiméricos anticlaudina 18.2 humanizados e seus usos BR112021016673A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962825955P 2019-03-29 2019-03-29
US62/825,955 2019-03-29
US201962859843P 2019-06-11 2019-06-11
US62/859,843 2019-06-11
US201962896758P 2019-09-06 2019-09-06
US62/896,758 2019-09-06
PCT/US2020/024432 WO2020205331A1 (en) 2019-03-29 2020-03-24 Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof

Publications (1)

Publication Number Publication Date
BR112021016673A2 true BR112021016673A2 (pt) 2021-10-13

Family

ID=72667032

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016673-4A BR112021016673A2 (pt) 2019-03-29 2020-03-24 Receptores de antígeno chiméricos anticlaudina 18.2 humanizados e seus usos

Country Status (12)

Country Link
US (1) US20220184126A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947468A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022527173A (cg-RX-API-DMAC7.html)
KR (1) KR20210144792A (cg-RX-API-DMAC7.html)
CN (1) CN113784980B (cg-RX-API-DMAC7.html)
AU (1) AU2020253792A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021016673A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132201A1 (cg-RX-API-DMAC7.html)
IL (1) IL286696A (cg-RX-API-DMAC7.html)
MX (1) MX2021011887A (cg-RX-API-DMAC7.html)
SG (1) SG11202109052YA (cg-RX-API-DMAC7.html)
WO (1) WO2020205331A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7840511B2 (ja) 2019-02-01 2026-04-06 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 抗クローディン18抗体及びそれらの使用の方法
WO2022122709A1 (en) * 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
CN115073606B (zh) * 2021-03-10 2025-05-02 上海莱馥医疗科技有限公司 一种靶向表达cldn 18.2的细胞的人源化嵌合抗原受体
CN113354739B (zh) * 2021-01-11 2022-08-23 上海莱馥医疗科技有限公司 一种靶向表达Claudin18.2细胞的嵌合抗原受体及其应用
KR20240044467A (ko) 2021-08-09 2024-04-04 하버 바이오메드 (상하이) 컴퍼니 리미티드 Cldn18.2-표적화 항체, 이중특이적 항체, 및 이들의 용도
AU2023276514A1 (en) * 2022-05-27 2024-12-05 Shenzhen Immunofoco Biotechnology Co., Ltd. Chimeric antigen receptor containing cldn18.2 single domain antibody and application thereof
KR20250087608A (ko) * 2022-10-10 2025-06-16 메디뮨 엘엘씨 클라우딘 18.2를 표적화하는 키메라 항원 수용체로 암을 치료하는 조성물 및 방법
WO2025255276A1 (en) * 2024-06-04 2025-12-11 Fred Hutchinson Cancer Center Anti-whitlow linker binding domains and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
IL282953B2 (en) * 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for the treatment of claudin-expressing cancers
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药(上海)有限公司 抗密蛋白18a2的抗体及其应用
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
MX2020009326A (es) * 2018-03-08 2020-10-08 Phanes Therapeutics Inc Anticuerpos anti-claudina 18.2 y usos de los mismos.

Also Published As

Publication number Publication date
JP2022527173A (ja) 2022-05-31
MX2021011887A (es) 2021-10-26
SG11202109052YA (en) 2021-10-28
IL286696A (en) 2021-10-31
EP3947468A1 (en) 2022-02-09
WO2020205331A1 (en) 2020-10-08
CN113784980B (zh) 2024-04-30
US20220184126A1 (en) 2022-06-16
AU2020253792A1 (en) 2021-09-09
CN113784980A (zh) 2021-12-10
CA3132201A1 (en) 2020-10-08
KR20210144792A (ko) 2021-11-30

Similar Documents

Publication Publication Date Title
US20220184127A1 (en) Humanized anti-dll3 chimeric antigen receptors and uses thereof
CN113784980B (zh) 人源化抗Claudin18.2嵌合抗原受体及其用途
CN113728007B (zh) 人源化抗叶酸受体1嵌合抗原受体及其用途
JP2024510739A (ja) 新規な細胞治療システム
CN119095879A (zh) 抗间皮素抗体及其用途
EP3340998B1 (en) Methods and compositions for cells expressing a chimeric intracellular signaling molecule
US20230220107A1 (en) Anti-Tumor Associated Antigen Antibodies and Uses Thereof
US20250136703A1 (en) Anti-il13ra2 antibodies and uses thereof
WO2024076864A2 (en) Anti-ror1 antibodies and uses thereof
HK40056378B (en) Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
HK40056036A (en) Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof
EP4608444A2 (en) Anti-egfrviii antibodies and uses thereof
HK40056381A (en) Humanized anti-dll3 chimeric antigen receptors and uses thereof
WO2025147472A1 (en) Anti-611-ctf p95her2 antibodies and uses thereof
WO2024182475A2 (en) Anti-ror2 antibodies and uses thereof
HK40119757A (en) Anti-il13ra2 antibodies and uses thereof
CN120344262A (zh) 抗-5t4抗体及用途
HK40056378A (en) Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]